| Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology DK Armstrong, RD Alvarez, JN Bakkum-Gamez, L Barroilhet, K Behbakht, ... Journal of the National Comprehensive Cancer Network 19 (2), 191-226, 2021 | 464 | 2021 |
| Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline PA Konstantinopoulos, B Norquist, C Lacchetti, D Armstrong, RN Grisham, ... Journal of clinical oncology: official journal of the American Society of …, 2020 | 305 | 2020 |
| BRAF mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer RN Grisham, G Iyer, K Garg, D DeLair, DM Hyman, Q Zhou, A Iasonos, ... Cancer 119 (3), 548-554, 2013 | 220 | 2013 |
| NCCN guidelines® insights: Ovarian cancer, version 3.2022: Featured updates to the NCCN guidelines DK Armstrong, RD Alvarez, FJ Backes, JN Bakkum-Gamez, L Barroilhet, ... Journal of the National Comprehensive Cancer Network 20 (9), 972-980, 2022 | 131 | 2022 |
| Clinical utility of prospective molecular characterization in advanced endometrial cancer TE Soumerai, MTA Donoghue, C Bandlamudi, P Srinivasan, MT Chang, ... Clinical Cancer Research 24 (23), 5939-5947, 2018 | 123 | 2018 |
| Clinical and morphologic characteristics of MEK inhibitor–associated retinopathy: differences from central serous chorioretinopathy JH Francis, LA Habib, DH Abramson, LA Yannuzzi, M Heinemann, ... Ophthalmology 124 (12), 1788-1798, 2017 | 111 | 2017 |
| Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer DM Hyman, Q Zhou, A Iasonos, RN Grisham, AG Arnold, MF Phillips, ... Cancer 118 (15), 3703-3709, 2012 | 104 | 2012 |
| Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer RN Grisham, BE Sylvester, H Won, G McDermott, D DeLair, R Ramirez, ... Journal of clinical oncology 33 (34), 4099, 2015 | 100 | 2015 |
| Placental site trophoblastic tumor: analysis of presentation, treatment, and outcome DM Hyman, L Bakios, G Gualtiere, C Carr, RN Grisham, V Makker, ... Gynecologic oncology 129 (1), 58-62, 2013 | 98 | 2013 |
| MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum BJ Monk, RN Grisham, S Banerjee, E Kalbacher, MR Mirza, I Romero, ... Journal of clinical oncology 38 (32), 3753, 2020 | 97 | 2020 |
| Low-grade serous ovarian cancer: state of the science B Slomovitz, C Gourley, MS Carey, A Malpica, IM Shih, D Huntsman, ... Gynecologic oncology 156 (3), 715-725, 2020 | 96 | 2020 |
| Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer RN Grisham, G Iyer, E Sala, Q Zhou, A Iasonos, D DeLair, DM Hyman, ... International Journal of Gynecologic Cancer 24 (6), 2014 | 86 | 2014 |
| Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study O Zivanovic, DS Chi, Q Zhou, A Iasonos, JA Konner, V Makker, ... Journal of Clinical Oncology 39 (23), 2594-2604, 2021 | 74 | 2021 |
| Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000–2013 A Oseledchyk, MM Leitao Jr, J Konner, RE O’Cearbhaill, D Zamarin, ... Annals of Oncology 28 (12), 2985-2993, 2017 | 74 | 2017 |
| Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management R Grisham, B Ky, KS Tewari, DJ Chaplin, J Walker Gynecologic oncology research and practice 5, 1-10, 2018 | 73 | 2018 |
| Ovarian cancer mutational processes drive site-specific immune evasion I Vázquez-García, F Uhlitz, N Ceglia, JLP Lim, M Wu, N Mohibullah, ... Nature 612 (7941), 778-786, 2022 | 70 | 2022 |
| Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes YL Liu, K Breen, A Catchings, M Ranganathan, A Latham, DJ Goldfrank, ... JCO oncology practice 18 (3), 201-209, 2022 | 44 | 2022 |
| Competitive Translation Efficiency at the Picornavirus Type 1 Internal Ribosome Entry Site Facilitated by Viral cis and trans Factors EY Dobrikova, RN Grisham, C Kaiser, J Lin, M Gromeier Journal of virology 80 (7), 3310-3321, 2006 | 43 | 2006 |
| Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models HC Wise, GV Iyer, K Moore, SM Temkin, S Gordon, C Aghajanian, ... Scientific reports 9 (1), 18882, 2019 | 42 | 2019 |
| The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer JL Meisel, DM Hyman, K Garg, Q Zhou, F Dao, M Bisogna, J Gao, ... Annals of oncology 25 (12), 2372-2378, 2014 | 42 | 2014 |
